References
- 1. Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol 2020;127:104370.10.1016/j.jcv.2020.104370719464832344321
- 2. Scialpi M, Scialp S, Piscioli I, et al. Pulmonary thromboembolism in criticall ill COVID-19 patients. Int J Infect Dis 2020 Apr 24.10.1016/j.ijid.2020.04.056718035232339717
- 3. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020.
- 4. Violi F, Pastori D, Cangemi R, et al. Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge. Thromb Haemost Published Online First: 2020 Apr 29.10.1055/s-0040-1710317729529032349133
- 5. Gris J, Quéré I, Pérez-Martin A, et al. Uncertainties on the prognostic value of D-dimers in COVID-19 patients. J Thromb Haemost 2020 Apr 28.10.1111/jth.14876726723732344457
- 6. Bowles L, Platton S, Yartey N, et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. N Engl J Med 2020 May 5.10.1056/NEJMc2013656721755532369280
- 7. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.10.1111/j.1538-7836.2006.01753.x16420554
- 8. Caraiola S, Jurcu C, Dima A, et al. Antiphosphatidylethanolamine Antibodies and Deep Vein Thrombosis in Lupus Patients with Antiphospholipid Syndrome. Rev Rom Med Lab 2018;26:243–50.10.2478/rrlm-2018-0009
- 9. Fan BE. Hematologic parameters in patients with COVID-19 infection. Am J Hematol 2020 Apr 27.10.1002/ajh.25847726747732339335
- 10. Cattaneo M, Bertinato EM, Birocchi S, et al. Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified? Thromb Haemost 2020 Apr 29.10.1055/s-0040-1712097751635632349132
- 11. Vulliamy P, Jacob S, Davenport RA. Acute aorto-iliac and mesenteric arterial thromboses as presenting features of COVID-19. Br J Haematol 2020 Apr 30.10.1111/bjh.16760726761832353183
- 12. Grillet F, Behr J, Calame P, et al. Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography. Radiology 2020; 201544.10.1148/radiol.2020201544
- 13. Thachil J. What do monitoring platelet counts in COVID-19 teach us? J Thromb Haemost 2020:14879.10.1111/jth.14879
- 14. Albu DE, Copotoiu M, Szmuk P, et al. Platelets and Infections Course notes. Rev Română Med Lab 2018;26 (4): 497-502.
- 15. Mendoza-Pinto C, García-Carrasco M, Cervera R. Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant). Curr Rheumatol Rep 2018;20(10):62.10.1007/s11926-018-0773-x
- 16. McNeil HP, Chesterman CN, Krilis SA. Immunology and Clinical Importance of Antiphospholipid Antibodies. Adv Immunol 1991;49:193–280.10.1016/S0065-2776(08)60777-4
- 17. Kravvariti E, Koutsogianni A, Samoli E, et al. The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. Autoimmun Rev 2020;19(4):102491.1810.1016/j.autrev.2020.10249132084592
- 18. Sarma P, Kaur H, Kumar H, et al. Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis. J Med Virol 2020 Apr 16.10.1002/jmv.25898726214432297988